Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies

Cited by (132)

Items 101–132 of 132

1. Mechanisms underlying immune-related adverse events during checkpoint immunotherapy
   Xiao Zhou, Xiang Chen, Leng Han, Hong Liu · 2022 · Clinical Science
2. Immunosuppressive Agents and Their Role in Managing Immunotherapy Toxicities in Melanoma
   Romaana Mir, Heather May Shaw, Paul Nathan · 2017 · Clinical skin cancer
3. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
   Ichiro Yamauchi, Takuro Hakata, Taku Sugawa, Daisuke Kosugi, Haruka Fujita, Kentaro Okamoto, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Norio Harada et al. · 2023 · Endocrine Journal
4. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors
   Hidefumi Inaba, Hiroyuki Ariyasu, Hisako Okuhira, Yuki Yamamoto, Hiroaki Akamatsu, Masahiro Katsuda, Masatoshi Jinnin, Isao Hara, Takashi Akamizu · 2020 · Trends in Immunotherapy
5. Endocrine Adverse Reactions of Tyrosine Kinase Inhibitors in Combination With Immune Checkpoint Inhibitors
   Wen Shao, Kaiwei Yang, Difei Lu, Ying Gao, Junqing Zhang, Y Q Zhang · 2025 · The Journal of Clinical Endocrinology & Metabolism
6. Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer
   Xinyong Zhang, Yuhua Wu, Jialin Lv, Xi Li, Li Ma, Jingying Nong, Hui Zhang, Na Qin, Quan Zhang, Guangli Shi et al. · 2019 · Interdisciplinary Sciences Computational Life Sciences
7. An Unusual Etiology of Hypothyroidism and New-Onset Insulin-Dependent Diabetes: A Rare Side Effect of Nivolumab
   Halah Alchalabi, Safa Albustani, Nusha Fareen, Ndausung Udongwo, Saira Chaughtai, Soemiwati Weidris Holland · 2022 · Cureus
8. Nivolumab-induced thyroid dysfunction in patients with lung cancer
   Ana Maria Ramos-Levi, Jacobo Rogado, J.M. Sánchez-Torres, Rámón Colomer, Mónica Marazuela · 2019 · Endocrinología Diabetes y Nutrición (English ed )
9. Clinical Significance of Thyroid Autoantibodies in Differential Diagnosis and Predicting the Course of Programmed Cell Death Protein-1 Inhibitor-Induced Thyroid Dysfunction
   Li Li, Xiaoxia Ding, Xihui Zhang, Shuangming Kong, Ming Chen · 2024 · Endocrine Practice
10. Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series
    Luigi Liguori, Angelo Luciano, Giovanna Polcaro, Alessandro Ottaiano, Marco Cascella, Francesco Perri, Stefano Pepe, Francesco Sabbatino · 2023 · Biomedicines
11. Effects of treatment with methimazole on circulating CD4+ and CD8+ T cells positive for programed cell death protein‐1 and on subsets of CD4+ T cells in untreated hyperthyroid patients with Graves' disease
    Nanako Hirao, Toshie Iijima, Dai Tanuma, Eriko Ohira, Hidetaka Kurai, Toshimitsu Shinzawa, Masato Kase, Shintaro Sakurai, Takuya Tomaru, Teruo Jojima et al. · 2022 · Clinical Endocrinology
12. The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists
    Maria V. Deligiorgi, Dimitrios T. Trafalis · 2022 · Expert Review of Clinical Pharmacology
13. Toxicities in Immune Checkpoint Inhibitors
    Sunyoung S. Lee, Matthew Loecher, Igor J. Puzanov · 2018 · Elsevier eBooks
14. Meta-Analysis of the Efficacy and Safety of Sintilimab in Combination With Chemotherapy for Advanced Non–Small-Cell Lung Cancer
    Liling Pan, Qiongqing Chen, Ningsheng Liang, Jinying Liang, Youjia Guo · 2025 · Current Therapeutic Research
15. Combined immune checkpoint inhibitor–induced type 1 diabetes: a rare but serious endocrinopathy
    Kasra Emami, Sonia Goyal, VISHAL AKULA, Peggy Nana Ama Amoakohene · 2026 · JCEM Case Reports
16. Immune-Related Adverse Toxicities and Clinical Management
    Michael Constantin Kirchberger, Lucie Heinzerling · 2018 · Springer eBooks
17. Endocrinopatias secundárias ao uso de inibidores de checkpoints imunológicos
    Matilde Jácome de Castro, David Veríssimo, Mafalda Marcelino, João Jácome de Castro · 2021 · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo
18. Endocrine Toxicities of Immunotherapy
    Manu Raj Pandey, Itivrita Goyal, Marc S. Ernstoff · 2020 · Elsevier eBooks
19. The Endocrinological Side Effects of Immunotherapies
    Anush V. Patel, Haisam Abid, Amrat Kumar · 2021 · IntechOpen eBooks
20. Programmed Cell Death 1 Receptor / Programmed Death-Ligand1 (PD‐1/PD‐L1 ) Inhibitors Alone or with Conventional Therapy versus Standard of Care for Head and Neck Cancer: A Systematic Review and Meta-Analysis
    Xin Huang, Jie Zhang, Hongying Ruan · 2021
21. A Case of Aggravation of Thyroid Goiter after Treatment with PD-1 Inhibitor for Breast Cancer in Patients with Underlying Hashimoto's Thyroiditis
    Hana Kim, Min Joo Kim, Young Shin Song, Sun Wook Cho · 2018 · International Journal of Thyroidology
22. Análise de disfunções tireoidianas induzidas pelo tratamento oncológico imunoterápico
    Karoline Laurentino Lopes Pinto, Ronan Wilk Guimarães, Gabriela Resende Vieira de Sousa · 2019 · Programa de Iniciação Científica - PIC/UniCEUB - Relatórios de Pesquisa
23. Cancer Immunotherapy Related Endocrine Adverse Effects
    Hana Kim, Sun Wook Cho, Young Joo Park · 2019 · International Journal of Thyroidology
24. 免疫チェックポイント阻害薬の副作用 ～糖尿病・内分泌代謝領域～
    田中 利明 · 2020 · 杏林医学会雑誌
25. Association Between Immune-Related Hypothyroidism and Survival Outcomes in Patients with Head and Neck Cancer Treated with Nivolumab
    Kojiro Hata, Keiichi Sasaki, Hiroyuki Watanabe, Munehiko Ikeda, Toshikazu Tsuji, Shigeru Ishida, Mio Ikebe, Ayako Kumagai, Nana Ozawa, Ryosuke Matsukane et al. · 2021 · Research Square
26. Endocrinopathies Associated With Immune Checkpoint Inhibitors
    Monica Girotra · 2021 · Elsevier eBooks
27. Nivolumab-Induced Thyroid Dysfunction
    Lohit Kumbar, Chitra Selvan, Y P Ganavi · 2021 · APIK Journal of Internal Medicine
28. Subacute thyroiditis as evidence of SARS-CoV2 related autoimmune disorders and case descriptions
    2021 · Iranian Red Crescent Medical Journal
29. Endocrine Complications of Biological Cancer Therapies
    Carla Moran · 2022
30. Cancer immunotherapy-associated endocrine complications and treatment strategies
    Koushik Sen, Madhuchhanda Adhikari, Chayan Biswas, Sukhendu Maity, Ankit Chatterjee, Kousik Pramanick · 2024 · Elsevier eBooks
31. A meta-analysis of the effectiveness and safety of Sintilimab combined with chemotherapy in the trea tment of advanced non-small cell lung cancer
    Liling Pan, Qiongqing Chen, Ningsheng Liang, Youjia Guo, Youjia Guo · 2024 · Research Square
32. Triggers for autoimmunity
    Catriona A. Wagner, Kenneth Smith, Judith A. James, Eddie A. James · 2024 · Elsevier eBooks